Ticker
LLY

Price
883.33
Stock movement up
+16.03 (1.85%)
Company name
Eli Lilly and Company
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
841.24B
Ent value
877.88B
Price/Sales
29.47
Price/Book
78.07
Div yield
0.59%
Div growth
14.97%
Growth years
7
FCF payout
63.44%
Trailing P/E
134.71
Forward P/E
75.43
PEG
10.22
EPS growth
-
1 year return
98.18%
3 year return
57.97%
5 year return
50.28%
10 year return
30.91%
Last updated: 2024-06-13

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share5.20
Dividend yield0.59%
Payout frequencyQuarterly
Maximum yield2.66%
Average yield1.51%
Minimum yield0.59%
Discount to avg yield-156.71%
Upside potential-61.05%
Yield as % of max yield22.15%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield0.59%
Current yield distribution99.92%
Yield at 100% (Min)0.59%
Yield at 90%0.77%
Yield at 80%1.01%
Yield at 50% (Median)1.44%
Yield at 20%2.04%
Yield at 10%2.29%
Yield at 0% (Max)2.66%

Dividend per share

Loading...
Dividend per share data
Years of growth7 years
CCC statusDividend Challenger
Dividend per share5.20
Payout frequencyQuarterly
Ex-div date15 May 2024
EPS (TTM)6.57
EPS (1y forward)11.71
EPS growth (5y)-
EPS growth (5y forward)13.18%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
LLYS&P500
DGR MR15.04%-16.32%
DGR TTM15.17%4.05%
DGR 3 years15.15%5.24%
DGR 5 years14.97%5.40%
DGR 10 years8.71%7.07%
DGR 15 years6.02%6.12%
Time since last change announced192 days
EPS growth (5y)-
EPS growth (5y forward)13.18%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM56.62%63.44%
Average--
Forward44.41%-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E134.71
Price to OCF118.74
Price to FCF150.93
Price to EBITDA99.75
EV to EBITDA104.10

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales29.47
Price to Book78.07
EV to Sales30.76

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count952.35M
EPS (TTM)6.57
FCF per share (TTM)5.87

Income statement

Loading...
Income statement data
Revenue (TTM)28.54B
Gross profit (TTM)21.91B
Operating income (TTM)8.11B
Net income (TTM)6.24B
EPS (TTM)6.57
EPS (1y forward)11.71

Margins

Loading...
Margins data
Gross margin (TTM)76.77%
Operating margin (TTM)28.43%
Profit margin (TTM)21.88%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.07B
Net receivables8.56B
Total current assets18.03B
Goodwill4.07B
Intangible assets7.21B
Property, plant and equipment0.00
Total assets49.49B
Accounts payable1.93B
Short/Current long term debt16.24B
Total current liabilities17.14B
Total liabilities38.71B
Shareholder's equity10.78B
Net tangible assets-629.80M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)7.08B
Capital expenditures (TTM)2.00B
Free cash flow (TTM)5.57B
Dividends paid (TTM)3.54B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity57.95%
Return on Assets12.62%
Return on Invested Capital23.12%
Cash Return on Invested Capital20.63%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open869.02
Daily high885.06
Daily low861.50
Daily Volume2.24M
All-time high883.33
1y analyst estimate380.75
Beta0.35
EPS (TTM)6.57
Dividend per share5.20
Ex-div date15 May 2024
Next earnings date8 Aug 2024

Downside potential

Loading...
Downside potential data
LLYS&P500
Current price drop from All-time high-0.10%-
Highest price drop-74.70%-56.47%
Date of highest drop5 Mar 20099 Mar 2009
Avg drop from high-30.31%-11.29%
Avg time to new high28 days13 days
Max time to new high4567 days1805 days
COMPANY DETAILS
LLY (Eli Lilly and Company) company logo
Marketcap
841.24B
Marketcap category
Large-cap
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Employees
39000
SEC filings
CEO
David Ricks
Country
USA
City
Indianapolis
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...